Tissue Regenix Group (LSE:TRX) Research & Development: £0.00 Mil (TTM As of Jun. 2025)


What is Tissue Regenix Group Research & Development?

Tissue Regenix Group LSE:TRX Research & Development is £0.00 Mil as of Jun. 2025. The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Tissue Regenix Group's Research & Development for the six months ended in Jun. 2025 was £0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2025 was £0.00 Mil.

Tissue Regenix Group  (LSE:TRX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Tissue Regenix Group Research & Development Related Terms

Tissue Regenix Group Research & Development Historical Data

* Premium members only.

The historical data trend for Tissue Regenix Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tissue Regenix Group Research & Development Chart

Tissue Regenix Group Annual Data
Trend Jan15 Jan16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.55 0.00 0.00 0.00 0.00

Tissue Regenix Group Semi-Annual Data
Jul15 Jan16 Jul16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Tissue Regenix Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of £0.00 Mil mean?
Tissue Regenix Group (LSE:TRX) has a Research & Development of £0.00 Mil as of Jun. 2025. Research and development expense is the total cost for research and development activities. View historical data on Tissue Regenix Group and its competitors.
Is Tissue Regenix Group's Research & Development too high?
Tissue Regenix Group's current Research & Development is £0.00 Mil.
How does Tissue Regenix Group's Research & Development compare to VRTX and REGN?
Tissue Regenix Group's Research & Development of £0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Tissue Regenix Group and its competitors. Tissue Regenix Group's current Research & Development is £0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tissue Regenix Group stock overvalued right now?
Tissue Regenix Group (LSE:TRX) has a current Research & Development of £0.00 Mil. The stock's GF Value™ is £0.87, compared to a current price of £0.07 — trading 91.7% below its estimated fair value. The current Research & Development is £0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Tissue Regenix Group (LSE:TRX), the current Research & Development is £0.00 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tissue Regenix Group Business Description

Address Lotherton Way, Unit 3, Phoenix Court, Garforth, GBR, LS25 2GY
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.